PNEAHS

Paroxysmal Neurologic Event Assessment in Habitual Settings

The first ambulatory probabilistic CDS platform for functional seizure assessment

— no EEG, no hospitalization, no motion-detection limitations

THE PROBLEM:

• 335,000 Americans live with functional dissociative seizures (FDS)

• 7.2-year average diagnostic delay

• $35,000–$40,000 per inpatient VEEG study — 5–7 day hospitalization required

• 250,000 Americans with FDS have never received VEEG

• ~40% of FDS events are non-convulsive — invisible to all motion-based wearable platforms

• $1.4B+/year in unnecessary testing and treatment

HOW PNEAHS WORKS:

Key differentiators:
• Detects convulsive AND non-convulsive FDS
• Calibrated probability with 95% CI — not a binary alert
• No training data required (event-internal approach)
• Platform-agnostic — any wrist wearable
• Non-locked CDS — all clinical decisions by treating physician

COMMERCIAL MODEL:

① Phase I — NAEC Epilepsy Centers
~300 centers · B2B SaaS · Additive revenue
Center net: $17.9K–$40.2K Yr1 · 5×+ ROI
$8.20M 5-yr · $2.79M ARR Year 5

② Phase II — HomeDirect
General Sleep Corp (Cleveland OH)
Zmachine HomeDirect logistics · LOS secured
~15K neurologists + ~35K psychiatrists unlocked

③ Phase II–III — SaaS Augmentation
API into existing wearable platforms
Per-assessment royalty ~$50–$75 · No PNEAHS hardware
LOS secured with several FDA-cleared wearable platforms

Total U.S. SAM:

~$60M+/year

CURRENT STATUS:

NIH SBIR Phase I (R43) · NINDS · $700K / 18 months
USPTO 63/901541 · Non-Provisional + PCT Oct 2026
Prelim data: 100% VEEG concordance (n=9)
Clinical partner: UHCMC Level IV NAEC